RavenQuest BioMed Inc (CNSX:RQB) Orbital Gardens Passes Health Canada Analytical Tests
RavenQuest BioMed Inc (CNSX:RQB) (OTCMKTS:RVVQF) (FRA:1IT) joins Midas Letter to discuss the quality and cleanliness of their cannabis products produced from the company’s revolutionary orbital garden technology. All cultivars passed analytical tests otherwise known as the COA (Certificate of Analysis) as required by Health Canada. It is becoming exceedingly rare among licensed producers that its grown cannabis have no traces of pesticides or Aflatoxins detected. The low microbial readings serve as evidence that the products produced by RavenQuest BioMed are safe. Mr. McDonald also discusses the company’s future direction heading into edibles and extracts market in Canada as well as their large growth plans for Europe, starting with Portugal and Norway.
Narrator: RavenQuest Biomed is a diversified cannabis company with divisions focused upon cannabis production, management services and consulting, and specialized research and development.
RavenQuest maintains a research partnership with McGill University focused on cultivar strain recognition, plant stabilization, and yield maximization of the cannabis plant.
The company focuses on partnerships with Indigenous communities.
RavenQuest Biomed trades on the CSE under the symbol RQB.
James West: Mathieu McDonald joins me now from RavenQuest Bio. Mathieu, welcome back.
Mathieu McDonald: It’s good to be here. Thank you, James.
James West: Mathieu, give me an update: what’s the latest on RavenQuest BioMed?
Mathieu McDonald: Okay, so over the last 20 months or so, this company has spent its time building out two state-of-the-art facilities. We’ve now got our revolutionary orbital garden technology up and running and fully populated throughout our Edmonton facility. So that has been great, and just recently, actually, over the last, about a week and a half ago, the company did a news release talking about the quality and the cleanliness of our cannabis product that’s been coming out of the orbital gardens.
The certificates of analysis did come back with close to zero microbial content in the plant material itself. We have been a consultant in the space, both privately and as a public company, since 2013; we’ve seen a lot of COAs in our time, and that is the lowest we’ve seen. So that’s very clean content coming out of the Edmonton orbital garden facility, and Health Canada just did a recent visit to that facility as well, to look over the new technology that we’ve done there, and everything came back and passed very well with Health Canada.
So we’re very excited about what’s been happening just in the distant past, with building the facilities, and then in the recent past, with the results that we’re getting out of the plant material itself. So that’s what’s been happening recently, and we’re quite excited about what’s been going on there.
James West: You bet. Okay, and tell me, how are you getting ready for the onset of the edibles market and the extracts market in Canada?
Mathieu McDonald: So yeah, we’re big believers – I mean, a lot of the MSOs in the US that we’ve spoken with, and we’ve seen some of those income statements, as well, that vaporization products are going to be a dominant product in the space, and we have a differentiated product that we’ve been working on at RavenQuest. What we’ve been working on is the formation for what we call a whole plant extract, or a whole plant extract product, that would be in a vaporization cartridge.
What that essentially means, and what makes it different from the other products out there that you’ve seen that would perhaps have, you know, a single compound or a bit of THC or CBD mixed into a carrier oil from a fractional distillate, the full plant extract product is very different, because it brings basically the entire plant material all the way through, and shines all the way through to the vaporization cartridge. So most of the plant material inside that cartridge – so, most of the material inside that cartridge is plant material, and will result in just a delightful flavour for the end user.
James West: Wow, fantastic. And you guys have started to make some moves into Norway, as well.
Mathieu McDonald: Well, we’ve got our Norwegian partners, BioCare, which we’ve spoken about. We signed a tentative agreement with them earlier this year, with a view towards major expansion into the European marketplace. So we’re very excited about the possibility of, in the near term, being able to bring that across into a definitive agreement with our Norwegian partners. And what that would mean would be beginning to expand into Portugal.
We’ve got two sites picked out in Portugal already, so we’ve got, basically, our troops lined up, and we’re ready to go with the expansion into Portugal. We’re very excited about that. If you see what’s been happening with the majors and you look at some of their revenues that have been coming across significant portions of revenue from some of the major producers is coming from across the pond in Europe. So we think that just further legitimizes our efforts to expand into the European market, and, you know, believe me, we believe that beyond Portugal, because our partners from Norway have significant funding capacity and significant political relationships throughout Europe, that the expansion starting in Portugal could indeed move beyond Portugal throughout Europe, as well.
James West: Mm-hmm. So is it RavenQuest Bio’s sort of plan to become like a Canopy of Europe?
Mathieu McDonald: Well, certainly, I mean, we’ve got large growth plans for Europe, starting with Portugal, and you know, I think it’s a true statement to say that there’s no dominant player in Europe. We think we’ve selected the right partner, and that partner has been inside our Edmonton facility. They’ve done due diligence, as you saw on the news release, with the heads of agreement with BioCare. They did due diligence across a number of very large companies here in Canada, and ultimately decided that they wanted to form a partnership with RavenQuest because of the ultra-modern facility and the orbital gardens, and all the benefits that the gardens bring: using less power, using less water, using less nutrients, and producing far more cannabis on a much smaller footprint.
This is really what we call Cannabis 2.0 from a perspective that we’re taking it to the next level as far as producing consistent plant material; the way that we can control that environment inside those orbital gardens with precision. Our European partners in Norway saw that. They’ve been inside those facilities. They’re very excited about the idea that we can basically drag and drop that technology in any climate, in any part of Europe, and really deliver the exact same consistent product to the end consumer or the end patient, no matter where you are in the world.
James West: Right. Awesome. So I guess that makes RavenQuest BioMed’s product is going to be very attractive to – sorry, EU GMP certifiable extraction processors and to companies making cannabinoids into APIs for the pharmaceutical industry.
Mathieu McDonald: Absolutely, and what pharmaceutical players that are looking at cannabis are looking for is consistency of product. And when you look at what RavenQuest has built, both with the orbital gardens and the precision control we have inside that plant environment, and combine that with what we’re doing with our partnership at McGill University – researching out exactly cultivar recognition, plant stabilization, and yield maximization – that addresses all of the things that pharmaceutical players are looking for to deliver a consistent product, end product, that they can work with and delivery various other products from that.
James West: Wow. That’s fantastic. All right, Mathieu, we’re going to leave it there for now. That’s a great update. Thank you so much for joining me today.
Mathieu McDonald: My pleasure. Thanks for having me, James. Have a great day.
James West: You too. Bye for now.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.